Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Analog Devices, Inc. (ADI) vs Cassava Sciences Inc (FLNA) Price & Performance

Analog Devices, Inc.
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Analog Devices, Inc. vs Cassava Sciences Inc — how do they compare? Analog Devices, Inc. trades at $385.24 (market cap $184.62B), while Cassava Sciences Inc trades at $1.19 (market cap $63.04M). The key difference: Analog Devices, Inc. is far larger — about 2928.6× Cassava Sciences Inc's market cap, and Analog Devices, Inc. pays a 1.16% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

ADIFLNA
Market Cap
$184.62B$63.04M
Sector
TechnologyHealth
52-Week High
$445.48$4.64
52-Week Low
$220.68$1.16
Enterprise Value
$189.87B-$23.53M
Dividend Yield
1.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Analog Devices, Inc.

Analog Devices (ADI) trades at $379.03, up 0.5% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q3-Q1 2026) and robust profitability (26% net margin). Recent acquisition of Empower Semiconductor and AI-driven semiconductor demand provide growth catalysts. Cash flow remains positive at $508M in 2025, though net cash flow is projected to decline to $61M in 2026.

Outlook remains positive with 79.6% analyst buy ratings and $471 consensus price target (24% upside). Key risks include elevated valuation multiples (P/E 57.9) and debt-to-asset ratio increase to 17.9%. The stock offers dividend income ($1.10 H1-26) while benefiting from semiconductor industry tailwinds, though margin sustainability and competitive pressures warrant monitoring.

Cassava Sciences Inc

FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.

The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Analog Devices, Inc.

Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.

Read more on ADI

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA